The Li ± Fraumeni cancer predisposition syndrome is associated with germline TP53 mutations in the majority of families. We have investigated cancer incidence in 34 Li ± Fraumeni families, according to their constitutional TP53 mutation status. Families with germline missense mutations in the core DNA binding domain showed a more highly penetrant cancer phenotype than families with other TP53 mutations or no mutation. Cancer phenotype in families carrying such mutations was characterized by a higher cancer incidence and earlier ages at diagnosis, especially of breast cancer and brain tumours, compared with families carrying protein truncating or other inactivating mutations (P=0.03 for all cancers, P=0.006 for breast cancers, P=0.05 for brain tumours). Proband cancers showed signi®cantly younger ages at diagnosis in those with missense mutations in the DNA binding domain than in those with protein inactivating mutations (P=0.031). In individuals with the former type of mutation, there was a signi®cantly lower proportion of tumours which showed loss of the wild-type TP53 allele (P=0.004). These results are consistent with observations in experimental systems which demonstrate that certain mutations exhibit gain of function and/or dominant-negative properties. Our results support an enhanced oncogenic potential for such mutations in human populations.
Introduction
The Li ± Fraumeni cancer family syndrome was described in 1969 on the basis of four families identi®ed from a study of childhood rhabdomyosarcoma in the United States (Li and Fraumeni, 1969) . A follow-up study of the four families and studies of cancer incidence among the families of a populationbased series and a hospital-based series of children with sarcomas established the validity of the syndrome (Li and Fraumeni 1982; Birch et al., 1984 Birch et al., , 1990 Strong et al., 1987) . Li et al. (1988) assembled 24 families ful®lling standard criteria to study characteristics of the syndrome. These criteria were: a proband with sarcoma before 45 years of age; a ®rst degree relative of the proband with any cancer below 45 years and another ®rst or second degree relative in the same lineage with any cancer before 45 years or sarcoma at any age. Families conforming to this de®nition are regarded as having classical Li ± Fraumeni syndrome (LFS). Families referred to hereafter as having LFS meet these criteria. The main LFS component cancers include bone and soft tissue sarcoma, breast cancer, brain tumours, leukaemia and adrenal cortical carcinoma. Multiple primary cancers are common.
In 1990 Malkin et al. reported germline mutations of the TP53 tumour suppressor gene in ®ve families with LFS. A further family was reported soon after (Srivastava et al., 1990) . In all six families missense mutations within exon 7 of the TP53 gene were detected. However, it soon became apparent that not all LFS families carried such mutations. Furthermore, mutations were identi®ed in certain families not meeting the LFS criteria and in unselected groups of patients with LFS component cancers (SantibanezKoref et al., 1991; Metzger et al., 1991; Sameshima et al., 1992; Wagner et al., 1994; Diller et al., 1995; Chen et al., 1995; Toguchida et al., 1992; Borresen et al., 1992; McIntyre et al., 1994) .
The mutations were not restricted to exon 7 but were widely spread and followed the distribution found in sporadic tumours (Hollstein et al., 1996) . Codons representing mutational hot-spots in sporadic tumours R175, G245, R248 and R273, were also more frequently mutated in the germline (Varley et al., 1997a) .
In most reports only exons 5 ± 8 of TP53, which include these hot-spots, have been analysed but two groups studied series of consecutively ascertained LFS families and analysed the whole coding region, exons 2 ± 11, of TP53. Frebourg et al. (1995) found germline TP53 mutations in eight of 15 LFS families. Our own group detected such mutations in six of 12 LFS families and in one or nine families designated Li ± Fraumeni like (LFL). Families were de®ned as LFL if they met the following criteria: a proband with childhood cancer or sarcoma, brain tumour or adrenal cortical carcinoma under 45 years with one ®rst or second degree relative with a typical LFS cancer (sarcoma, breast cancer, brain tumour, leukaemia or adrenal cortical carcinoma) at any age and another ®rst or second degree relative in the lineage with any cancer before 60 years (Birch et al., 1994) .
Our series has recently been extended to include 39 families (21 LFS and 18 LFL) and non-coding as well as coding regions of TP53 were sequenced using automated methods. All families reported as negative in our original study were re-sequenced using these methods. Detected mutations were con®rmed in at least one other family member (Varley et al., 1997b) . Following this extensive analysis, mutations were detected in 71% of LFS and 22% of LFL families, higher proportions of mutation-positive families than reported by other groups. The 19 mutations included nonsense and missense mutations and mutations in non-coding regions of the gene. It is notable that ®ve mutations (26%) occurred outside the hot-spot regions of exons 5 ± 8.
In other tumour suppressor genes (e.g. RB1 APC and BRCA1) the majority of mutations result in loss of function, giving rise to absent or truncated proteins. Mutations described in TP53 are mostly missense and may give rise to proteins showing a gain of function relative to the wild-type protein (Dittmer et al., 1993) . Furthermore, certain TP53 mutants may act in a dominant-negative fashion blocking normal wild-type functions (Milner and Medcalf, 1991) . The wild-type protein possesses a range of properties. The aminoterminus constitutes the transactivation domain and includes the ®rst of ®ve evolutionarily conserved regions. The central core domain, spanning codons 100 ± 293, is responsible for sequence-speci®c DNA binding and includes conserved regions II ± V. TP53 functions as a tetramer and the carboxy-terminal domain is responsible for oligomerization.
The crystal structure of the core DNA binding domain suggests that codons representing mutational hot-spots encode residues that either directly contact DNA, including R248 and R273, or which occupy key positions with respect to the maintenance of the threedimensional structure of TP53. The latter includes R175 and G245. It is the proteins corresponding to these mutations which show gain of function or dominant-negative properties in experimental systems. (Fields and Jang, 1990; Soussi et al., 1990; El-Deiry et al., 1992; Dittmer et al., 1993; Srivastava et al., 1993; Cho et al., 1994) . In vitro and in vivo assays of randomly generated mutations at residues within the carboxy-terminus of TP53 demonstrated loss of ability to transactivate target genes and failure of G 1 arrest following DNA damage for certain mutations (Ishioka et al., 1995) . However, studies of mouse TP53 show that loss of the tetramerization domain may not necessarily result in loss of transactivation and tumour suppressor properties (Shaulian et al., 1993) . On the basis of studies showing preferential expression of wildtype protein in constitutional samples from a patient heterozygous for a nonsense mutation to TP53 and readily detectable mutant m-RNA in tumour tissues, Horio et al. (1994) suggested that the associated mild familial aggregation of cancers may indicate heterogeneity in clinical phenotype depending on type of germline TP53 mutation. The properties of wild-type and mutant TP53 proteins in in vitro and in vivo assays suggest therefore, that the malignant potential conferred by mutations may vary according to the type and position of the mutation as a consequence of their eect on normal protein structure and function.
We have assembled a large series of welldocumented LFS and LFL families in whom constitutional DNA samples have been extensively analysed for TP53 mutations. We have detailed pedigree information on each family including cancer aected and unaected members. We have been able to obtain histopathological material for diagnostic review for a high proportion of cancers and pathology reports on the majority of the remainder. We are therefore in a unique position to examine possible phenotypic variations in Li ± Fraumeni families with and without TP53 mutations and to compare families with dierent types of mutations. To address this issue we have analysed cancer occurrence in our families according to their TP53 mutation status. The results presented below have important implications for clinical management of families and individuals carrying TP53 mutations. The results raise questions of clinical importance about the biology of malignant disease associated with these mutations.
Results

Study subjects
Twenty LFS and 14 LFL families strictly conforming to the criteria stated above were eligible for the study. Full TP53 sequence data were available on all families. A cohort of individuals from eligible families was established which included all ®rst and second degree relatives of probands in the cancer lineage regardless of their cancer status and whether or not they had been tested for a germline TP53 mutation. Age, site and sexspeci®c cancer incidence within this cohort was calculated. Among the 34 families, 309 ®rst and second degree relatives of probands with 132 eligible neoplasms were included in the cohort. The distribution of cancers by age and diagnostic group is given in Table 1 . 
Mutation status in families
Two types of TP53 mutations were de®ned. Type A included missense point mutations within the core DNA binding domain, encompassed by codons 100 ± 293. These mutations result in full length but functionally compromized proteins and include those which can act in a dominant-negative fashion and those which exhibit a gain of function in experimental systems. Type B mutations included any outside the core DNA binding domain and any protein-truncating mutation within the DNA binding domain. Thus, Type B mutations lead to premature termination or result in a non-functional protein.
The families were partitioned according to whether they carried a Type A, Type B or no germline TP53 mutation. Type A mutations occurred in 12 families (nine LFS, three LFL) and nine of these were at codons known to be mutational hot-spots in sporadic tumours. One deletion-insertion which remained in frame was regarded as a large point mutation and therefore classi®ed as Type A. Seven families had Type B mutations (®ve LFS, two LFL) including two point mutations creating a STOP codon, a deletion of two base-pairs resulting in a frame-shift, two mutations aecting splicing, a deletion of 167 base pairs in exon 1, and a point mutation in exon 10 within the tetramerization domain (Table 2 ). Further details of the families and discussion of the 19 mutations are presented by Varley et al. (1997b) .
Analysis of observed and expected cancers
Expected numbers of cancers were calculated for each of the three groups of families based on the incidence of cancers over the entire cohort. Expected numbers were compared with observed numbers under the null hypothesis that cancer rates are equal in all three groups. Chi-squared tests on two degrees of freedom were carried out and two-tailed P values calculated. Observed and expected numbers of cancers in Type A families were then compared with observed and expected numbers in Type B families. Separate analyses were performed with respect to: breast cancers; central nervous system (CNS) tumours; sarcomas; leukaemia and non-Hodgkin's lymphoma; gastrointestinal tract cancers; carcinomas and unspeci®ed cancers of other sites; and other speci®ed cancers. In addition, analyses of observed and expected second and subsequent primary cancers and of cancers diagnosed in the age groups 0 ± 14 years, 15 ± 44 years and 45 years and above respectively, were carried out. Table 3 shows the results of the analysis comparing cancer rates in families with Type A, Type B and no germline TP53 mutation. For all cancers together, there was a highly signi®cant dierence comparing observed and expected numbers of cancers in the three groups of families. The highest observed to expected ratio was seen in families with Type A mutations and the lowest in families with no mutations. When dierent types of cancers were analysed, breast cancers, CNS tumours and bone and soft tissue sarcomas all showed statistically signi®cant dierences in observed and expected numbers among the families.
Comparisons of cancers among groups of families
For breast cancers and CNS tumours, families with Type A mutations had markedly elevated observed to expected ratios. For bone and soft tissue sarcoma, the most marked dierence was the low observed to expected ratio among families with no mutations. No signi®cant dierences were observed between families with respect to leukaemias and lymphomas, other types of cancers and second and subsequent primaries. In a variety of assays this mutant protein is completely non-functional. The mutation has therefore been classi®ed as a type B (Ishioka et al., 1995; Varley et al., 1996) higher rate of cancers than Type B families. When dierent cancers were analysed separately, the most striking results were obtained for breast cancers and CNS tumours with higher observed to expected ratios in Type A families. Dierences in observed to expected ratios of other groups of cancers in families with Type A and Type B mutations did not approach statistical signi®ance (Table 4) . Results of analyses of cancer occurrence by age are shown in Table 5 . Considering all cancers together, there was a dierence of borderline statistical signi®cance for paediatric cancers, with a higher observed to expected ratio in families with Type A mutations. For cancers 15 ± 44 years of age there was a signi®cantly higher rate among Type A families but no dierence between the families for cancers over 45.
Comparisons of cancers in families with
Analysis of breast cancers under 45 years showed signi®cantly higher rates in families with Type A mutations. For CNS tumours the dierence was of borderline signi®cance.
Comparisons of proband characteristics
There were no dierences in sex distribution of probands and no dierences in the type of cancer in the proband (soft tissue sarcoma, bone tumour or other cancers) comparing the three groups of families. When ages of probands with Type A and Type B mutations were compared, a signi®cant dierence emerged (P=0.031), probands with Type A mutations being younger. 
Discussion
The present series of families is unique in several respects. First, the families have been systematically ascertained according to pre-de®ned standard criteria which were strictly applied. Second, information on dates of birth, dates of death and ages is available on a de®ned set of family members which includes the unaected as well as cancer aected individuals within each family. Third, the cancer diagnoses have been medically veri®ed in a very high proportion of individuals and for over half of the cancers histopathological material has been reviewed for this study. Fourth, an extensive molecular analysis of the TP53 gene in constitutional samples from each family has been carried out to include both coding and noncoding regions of the gene. The extent and detail of this analysis is unprecedented. Furthermore, in each family in whom a mutation was detected, the biological signi®cance of the mutation has been assessed and segregation of the mutation with cancers in the families demonstrated (Varley et al., 1997b; Boyle et al., 1998 ; R Camplejohn personal communication). These features have enabled us to undertake a study to determine whether there are phenotypic variations in terms of cancer incidence in Li ± Fraumeni families according to their constitutional TP53 genotype. Results of analyses of cancer incidence in the families strongly suggest that those families carrying missense point mutations within the DNA binding domain of TP53, show a more highly penetrant cancer phenotype than families with protein truncating or protein inactivating mutations or families in whom no TP53 mutation has been detected. Statistically signi®cant dierences between the three groups of families were observed and perhaps more importantly there were signi®cant dierences when families with Type A mutations were compared with families with Type B mutations. Surprisingly, families with Type B mutations had a cancer phenotype which appeared to resemble families with no mutations more closely than families with Type A mutations.
The more highly penetrant phenotype conferred by the Type A mutations was characterized by an overall higher cancer incidence and speci®cally a higher incidence of breast cancers and CNS tumours. It is also interesting to note that all cases of childhood onset adrenal cortical carcinomas occurred in individuals with Type A mutations. The higher incidence of cancers in families with Type A mutations was restricted to cancers diagnosed under 45 years of age, suggesting that older onset cancers included a number of sporadic cases.
Several approaches have demonstrated that in experimental systems, naturally occurring mutant p53 proteins vary in their biochemical and biological properties. These include eects exerted on in vitro cell lines and the tumorigenicity of cell lines expressing mutant p53 when injected into nude mice (Dittmer et al., 1993; Milner and Medcalf, 1991; Chen et al. 1993; Frebourg et al., 1992; Kawamura et al., 1996) . Each of the hot-spot mutations within the DNA binding domain constitutionally present in our families, including mutations at codons 175, 245, 248 and 273, have been shown to exhibit gain of function and/or dominant-negative properties in at least some assays. Dittmer et al. (1993) demonstrated gain of function properties for mutant p53 products including mutations in codons 175, 248 and 273. They observed that their data gave rise to the prediction that tumours with mutant missense p53 proteins may be more aggressive or have a poorer prognosis than tumours with no p53 protein (loss of function mutations).
Our data demonstrate that such mutations in the human germline give rise to a higher incidence of cancers with an earlier age at onset than constitutional mutations resulting in absent or truncated proteins. These data therefore support the concept of a greater oncogenic potential for mutations which show a gain of function or dominant-negative properties experimentally. In a previous study (Varley et al., 1997c) we demonstrated that only 44% of tumours from members of 14 of the above families showed loss of wild-type T53 allele. Analysis of the data on loss of constitutional heterozygosity (LOH) according to type of mutation showed that all tumours which did not show LOH occurred in individuals with Type A mutations (P=0.004) ( Table 6 ). These data provide further evidence of a greater oncogenic potential for such mutations in human tissue.
Breast cancers carrying somatic mutations in zinc binding domains of TP53 appear to show more aggressive behaviour and have a worse prognosis than tumours with other or no TP53 mutations (Aas et al., 1996; Borresen et al., 1995) . The zinc binding domains include codons 175, 245 and 248. It may be that cancers developing in individuals with constitutional mutations in these domains also carry a poor prognosis. In this context, we have found that the mean survival for all cancers occurring in a large family carrying a mutation to codon 175 was 11 months (Varley et al., 1995) . The crystal structure of the core DNA binding domain of TP53 has shown that the mutational hotspot residues occupy positions critical to the function of the p53 protein. Two classes of mutation within the DNA binding domain emerge. Class I are those which aect residues which directly contact DNA and include R248 and R273. Class II mutations aect residues which stabilise and maintain the structure of the protein. These residues include R175 and G245. These most frequently mutated residues occupy positions at or near the DNA interface. Interestingly, although Y220, which is constitutionally mutated in one of our families, does not fall into this category, it appears that this residue is structurally important (Cho et al., 1994) and mutations to Y220 might appropriately be categorized as Class II.
Type A mutations as de®ned by us in the present analyses, include both Class I and Class II mutations. Small numbers of families would not permit separate analyses at present but as our series increases, future analyses of genotype and phenotype in LFS families should consider Class I and Class II mutations in the core DNA binding domain separately.
Another possible approach would be to analyse those mutations which exert a dominant-negative eect on wild-type protein which include mutations at codons 175 and 245 separately from those which do not appear to interact with wild-type protein in this way. Dominant-negative mutant proteins eectively create cells which have no functional wild-type p53 protein. Individuals with constitutional dominantnegative mutations therefore represent the human equivalent of mice hemizygous for wild-type p53 which contain a dominant-negative mutant transgene. Such mice develop tumours at an earlier age than mice which are null/wild type but without the transgene (Harvey et al., 1995; Purdie et al., 1994) . It might be predicted therefore that human constitutional dominant-negative mutations would confer a more penetrant cancer phenotype.
While the common hot-spot mutations in the DNA binding domain have been fairly well characterized with respect to their biochemical properties, other mutations which occur less frequently both somatically and in the germline have been less well characterized. It is therefore possible that 1 or 2 mutations which we have classi®ed as Type A may show loss of function and 1 or 2 classi®ed as Type B may have a dominantnegative eect. However, any such misclassi®cation would tend to dilute the eect we have observed. That is, a more highly penetrant cancer phenotype associated with gain of function/dominant negative mutations. In these circumstances the true dierence in phenotype between Type A and Type B families would be even greater than indicated by the present analyses. The precise sub-classi®cation of mutations within the core DNA binding domain will depend on results of studies in progress.
In summary, we have demonstrated distinct phenotypic dierences between families with Li ± Fraumeni Syndrome according to their constitutional TP53 mutation status. Missense point mutations in the core DNA binding domain of TP53 confer a phenotype characterized by a higher incidence of cancers particularly breast and CNS tumours with earlier ages of onset than in families with mutations leading to truncated or non-functional proteins. Speci®c cancer risks within families would therefore appear to depend on the extent to which wild-type TP53 function is compromized. The higher penetrance associated with single base changes in the mutational hot-spot regions would support a gain of function for these mutations. Risk assessment in families presenting for genetic counselling and possible predictive testing must take into account the type of mutation segregating in individual families.
Future questions to be addressed include more detailed analyses of phenotype in relation to genotype to take account of the biological properties of mutations as demonstrated in experimental systems. Predicted sensitivity of TP53 mutation carriers to exogenous carcinogens is also an issue in patient management. In this context it should be noted that breast cancers, which numerically are the most frequent cancers associated with the syndrome, have a very early age of onset. In the present series 74% were under 40 years at diagnosis, the youngest breast cancer patient was 21. If mammographic screening were to be contemplated, this would have to begin in late adolescence at a time when the breast is particularly sensitive to the carcinogenic eects of ionizing radiation. Response to treatment and prognosis in these patients also represents an area for investigation since variation in response to cytotoxic therapy according to mutation type might be predicted.
Although families with germline TP53 mutations are uncommon, such families provide important models of genetic predisposition to cancer which have wider implications. Somatic mutations to TP53 are the most common genetic events in human malignancies and studies of families with germline TP53 mutations can provide important information on the biology of common sporadic tumours.
Materials and methods
Families conforming to the criteria for LFS or LFL as de®ned above were systematically ascertained from four sources. In all families, details of at least ®rst and second degree relatives of probands were obtained by interview. Copies of death certi®cates, medical records and histopathological material relating to reported tumours were obtained as far as possible. Blood samples were obtained from aected and unaected family members, depending on accessibility of individuals and willingness to participate. Histopathological material was also used as a source of DNA. Constitutional DNA samples were analysed for TP53 mutations in coding and non-coding regions of the gene. The molecular analyses are described in detail elsewhere (Varley et al., 1997b) .
On the basis of all available information, families were classi®ed as LFS, LFL or ineligible. The criteria for LFS and LFL as stated above were strictly applied and non-invasive tumours (including in situ lesions and tumours of uncertain behaviour) were regarded as ineligible. Following histopathological and clinical review, ®ve families included in our recent study of TP53 germline mutations (Varley et al., 1997b) were considered ineligible for the present analyses. In three of these (families 253, 348 and 352) breast tumours in family members critical to ful®lling the LFL criteria were found on review to be intraduct carcinomas with no evidence of invasive carcinoma. In family 353 there was no individual who ful®lled the second point of the LFL criteria (®rst or second degree relative of proband with typical LFS cancer) and in family 2634 there was no individual who ful®lled the proband criteria (any childhood cancer or sarcoma, brain tumour or adrenocortical carcinoma before 45 years of age). A further family (1799) previously regarded as LFS was reclassi®ed as LFL since a connective tissue tumour thought to be a sarcoma was found to be benign following review of diagnosis. Therefore 34 families, 20 LFS and 14 LFL, in whom full TP53 sequence data were available, were included. Fourteen families were ascertained through the MCTR (eight LFS, six LFL), 10 through the UKCCSG (nine LFS, one LFL), four through Medical Oncology clinics (two LFS, two LFL) and six through Genetics clinics (one LFS, ®ve LFL).
The pedigrees of these families were inspected to determine which family members were in the cancer lineage. This was de®ned by initially identifying the cancers which resulted in the family being classi®ed as LFS or LFL and then using an iterative process whereby every immediately preceding generation in the line was examined to ®nd the earliest generation containing an individual with cancer under 60 years of age or a sarcoma at any age. That individual and all their descendents are in the cancer lineage. If only a single individual in the earliest generation was aected, all their siblings and siblings' descendants are classi®ed as not known, otherwise all their siblings and siblings' descendants are in the cancer lineage. All their ancestors are classi®ed as not known. Remaining family members are not in the cancer lineage. If, during the iterative process, qualifying cancers are found on both the maternal and paternal sides of the family, then both parents, the parents siblings and ancestors and the parents siblings' descendants must be classi®ed as not known.
A cohort of 309 ®rst and second degree relatives of the probands who were in the cancer lineage was identi®ed. One hundred and thirty-two malignant and CNS tumours, including second and subsequent cancers, were diagnosed in this cohort. Person-years at risk were calculated by sex, age group (0, 1 ± 4, 5 ± 9, 10 ± 14 . . . 80± 84, 85+) and mutation group. Observed cancers, including second and subsequent cancers, were counted by sex, age group, mutation group and diagnostic group. Person years at risk and observed cancers in the parents prior to the birth of the proband and in the grandparents prior to the birth of the relevant parent were excluded because cancer incidence in these time intervals is low. Expected cancers were calculated from overall incidence rates derived from person-years at risk and observed cancers summed over appropriate mutation groups.
Observed and expected second and subsequent cancers were calculated in a similar way from those cohort members who had been diagnosed with at least one cancer. Personyears at risk and observed cancers were calculated over the period of life from the diagnosis of the ®rst cancer to the date of last follow-up or death.
